lupus and cardiovascular disease
TRANSCRIPT
![Page 1: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/1.jpg)
Systemic Lupus and Cardiovascular Disease
A Brief Overview
Mark A. Menegus, MD, FACC, FSCAI
October 2010
Disclosures--none
![Page 2: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/2.jpg)
ACR Criteria for Lupus*
• Malar Rash• Discoid Rash• Photosensitivity• Oral Ulcers• Arthritis• Serositis (pericard.-
pleura)• Renal Disorder: (eg
proteinuria)
• Neuro Disorder: (seizures/psychosis)
• Heme Disorder: (low platelets, etc)
• Immunologic Disorder (AntiDS DNA; Anti Sm; APL Ab)
• + Antinuclear Ab (ANA)
4 required to include in SLE cohort * These are NOT Diagnostic Criteria
![Page 3: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/3.jpg)
Lupus
![Page 4: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/4.jpg)
Lupus and Inflammation
• SLE is a chronic, inflammatory disease with circulating Autoantibodies (“anti-self”); activated T cells (tissue autoimmunity); immune complexes (Antigen-Antibody) and inflammatory Cytokines (cell messenger proteins)
• Lupus Therapy over the last 4 decades has converted a rapidly fatal disease into a chronic condition
![Page 5: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/5.jpg)
Cardiac Involvement in Lupus
All “layers” of the heart can be involved:
1) Pericardium
2) Myocardium
3) Valves
4) Conducting System
5) Coronary Vessels
![Page 6: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/6.jpg)
Pericardium
• The thin layer(s) covering the heart
• Inflammation (Pericarditis) occurs in 11-54% of Lupus patients
• Often occurs at Onset or with Relapses
• Pericarditis is the most characteristic feature and is one of the ACR/ARA Classification Criteria for Lupus
• Treated with NSAIDs or Steroids
A. Doria; Lupus; 14; 2005
![Page 7: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/7.jpg)
Pericardium and Pleura
![Page 8: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/8.jpg)
Myocardium
• The active muscle (“pump”) of the heart
• Inflammation (“Myocarditis”) occurs in 7-10% of cases (and is treated with Steroids)
• Myocardial Dysfunction, however, is more commonly due to early coronary artery disease, hypertension, renal failure, valvular disease
Doria; Lupus; 2005
![Page 9: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/9.jpg)
Myocardium and Valves
![Page 10: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/10.jpg)
Cardiac Valves
• Connective Tissues that control blood flow into and out of the heart
• Inflammatory lesions usually on Mitral or Aortic Valves (both active and healed)
• Some thickening seen in 40-50% of Echos• “Verrucous” or Libman-Sacks lesions
characteristic but not usual• Significant clinical valve pathology is
unusual (leaking or narrowing)
Doria; Lupus; 2005
![Page 11: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/11.jpg)
Focal Mitral Valve Thickening (51 year-old Lupus patient)
Farzaneh-Far; ArthritisRheum; Dec 2006
![Page 12: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/12.jpg)
Conducting System
• Carries the electrical impulses from the heart’s “pacemaker” (Sinus Node) in the atria (top chambers) thru the Atrioventricular Node to the ventricular (pump) muscles (lower chambers)
• Conduction “Block” rare in adults
• Seen in 2% of children born to mothers with Anti-Ro/SSA positive Lupus
Doria; Lupus; 2005
![Page 13: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/13.jpg)
Coronary Arteries
• Larger (surface) and smaller (myocardial) vessels that supply the working muscle of the heart
• Coronary Artery Disease in 6-10%; Lupus patients have a 4-8 fold increased risk of developing CAD
• Smaller vessel inflammation (vasculitis)-usually in younger patients with active SLE
• Larger vessel inflammation (atherosclerosis)-usually in older patients with long-standing SLE
Doria; Lupus; 2005
![Page 14: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/14.jpg)
Coronary Artery Stenoses (Atherosclerosis)
![Page 15: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/15.jpg)
Acute Coronary Thrombosis
![Page 16: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/16.jpg)
Definitions:
• ACS: Acute Coronary Syndrome, ie chest pain with/without blood enzyme elevation
• MI: Myocardial Infarction—”heart attack”
• PCI: Percutaneous Coronary Intervention, ie angioplasty/stent placement
• CABG: Coronary Artery Bypass Grafting, ie open heart bypass surgery
![Page 17: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/17.jpg)
Vascular Disease in Lupus
Prevalence of M.I., Angina and Peripheral Vascular Disease in Lupus Cohorts:
1) Toronto Lupus Cohort = 10%
2) Baltimore Cohort = 8.3%
3) Pittsburgh Cohort = 6.7%
Mean Age at 1st “Event” was 48-49 years old
Frequently affected: Pre-menopausal Women
Bruce I; Rheum. Dis. Clinics North America 26; 2 May 2000
![Page 18: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/18.jpg)
Cohort Commonality
The Toronto, Baltimore and Pittsburgh Lupus Cohorts each had clinical predictors for early Coronary Heart Disease.
The Three Cohorts all shared two common
features: a. Older Age at Diagnosis of SLE
b. Dyslipidemia (high cholesterol)
Bruce, I.; Rheum.Dis.Clinics North Amer.; 26; 2 May 2000
![Page 19: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/19.jpg)
Vascular Disease and Lupus
Hahn,B; NEJM; Dec 18, 2003
![Page 20: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/20.jpg)
Inflammation and Vascular Disease
• Atherosclerosis is also a chronic inflammatory disorder, with characteristic Cellular (monocyte-macrophage) and Circulating (C-reactive protein-”CRP”)
• 40% of Lupus patients ages 40-45 have established Carotid Artery Plaque
• Later mortality in SLE is more frequently due to Atherosclerosis—aggressive risk reduction is essential.
Salmon; Curr.Opin.Rheum; 13(5) Sept 2001
![Page 21: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/21.jpg)
Carotid Plaque and Lupus
• 197 registry patients from H.S.S.-NYC
• Well matched to controls by age, sex, BP and race
• Carotid Ultrasound (focal protrusion > 50% of wall thickness= Plaque)
• Cardiac Echo to examine valve thickening
• Measured hs-CRP and routine serology
Roman, M: NEJM; 349: Dec 18, 2003
![Page 22: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/22.jpg)
Carotid Ultrasound-I.M.T.
![Page 23: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/23.jpg)
Carotid Plaque and Lupus
Roman; NEJM; 2003
![Page 24: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/24.jpg)
Carotid Ultrasound-Plaque
![Page 25: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/25.jpg)
Carotid Plaque and Lupus
Roman; NEJM; 2003
![Page 26: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/26.jpg)
Coronary Calcium and Lupus
• 65 lupus patients (85% female; avg 40 yo)
• 69 age, sex, race-matched controls
• Excluded prior history vascular disease (stroke, MI, angina)
• Assessed SLEDAI and SLE Damage Scores
• Measured degree (score) of Coronary Calcium on EBCT scan
Asanuma,Y; NEJM; 349; Dec 18 2003
![Page 27: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/27.jpg)
Coronary Calcium and Lupus
Asanuma; NEJM; Dec 18, 2003
*
*
*
![Page 28: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/28.jpg)
Calcified and Non-Calcified Coronary Plaque
Kiani, A; J.Rheumatology;37: 579; 2010
![Page 29: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/29.jpg)
Coronary Calcium and Lupus
Asanuma; NEJM; Dec 18, 2003
![Page 30: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/30.jpg)
![Page 31: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/31.jpg)
![Page 32: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/32.jpg)
Summary-Vascular Disease and Lupus
• Odds ratio for Atherosclerosis in SLE patients= 4.8 in Roman’s study
9.8 in Asanuma’s study• Neither found significant correlation with
inflammatory markers (CRP, etc)• Both found less disease in patients with
greater use of steroids or chloroquine• Traditional risk factors are often under-
treated in the SLE population
Hahn, B; NEJM; Dec 18, 2003
![Page 33: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/33.jpg)
Framingham Risk Assessment
• Ongoing study of Cardiovascular Risk in a US cohort; study inception in 1940’s
• Allows calculation of Expected 10 year risk of developing Coronary Disease
• Factors in:
Age/Sex Diabetes
Blood Pressure LV Hypertrophy
Smoking
Cholesterol
![Page 34: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/34.jpg)
Lupus-Beyond Framingham
• 296 Canadian and Parisian Lupus patients• Excluded 33 with prior Vascular Event• Tabulated vascular outcomes (non-fatal MI, fatal
Coronary event or Stroke) over 8.6 years • Compared these to the “expected” outcome
rates by traditional Framingham risk assessment.
• Observed events far exceeded expected events in this lupus cohort (note: retrospective study)
Esdaile; Arthrit.Rheum.;44; Oct. 2001
![Page 35: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/35.jpg)
Beyond Framingham
Esdaile; Arthritis.Rheumat; 44; Oct. 2001
![Page 36: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/36.jpg)
Myocardial Perfusion (Blood Flow) Imaging
![Page 37: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/37.jpg)
Perfusion Imaging in Asymptomatic Lupus Patients*
Nikpour, M; J. Rheumatology; 36: 2009* f/u for 8.7 years
![Page 38: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/38.jpg)
© 2001 L ippincott Williams & Wilkins , Inc. P ublis hed by L ippincott Williams & Wilkins , Inc. 2
T able 1Accelerated atheros cleros is in s ys temic lupus erythematos us : implications for patient management.S almon, J ane; R oman, Mary
C urrent Opinion in R heumatology. 13(5):341-344, S eptember 2001.
T able 1 . S trategies to reduce atheros clerotic cardiovas cular dis eas e in patients with s ys temic lupus erythematos us AS C VD, atheros clerotic cardiovas cular dis eas e; B P , blood pres s ure; L DL , low-dens ity lipoprotein.
![Page 39: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/39.jpg)
Statins and Vasodilation in SLE
• 64 women with SLE (avg age 31) rec’d Atovastatin 20mg x 8 weeks
• 24 women with SLE (avg age 34) rec’d Placebo x 8 weeks
• 16 healthy female controls
Baseline and 8 week analysis: Brachial Artery Ultrasound with BP cuff “reactive hyperemia” –artery diameter and flow
G.Ferreira; Rheumatology 46; 1560; 2007
![Page 40: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/40.jpg)
Flow-Mediated Dilation (%) STATIN PLACEBO
Ferreira; Rheumatology 2007
![Page 41: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/41.jpg)
Atorvastatin and Vasodilation
• At 8 weeks of active treatment, Total and LDL Cholesterol and TG all decreased*
• Resting Diameter and Flow-Mediated dilation of Brachial Artery increased*
• SLEDAI scores decreased (4.47 to 3.08)* but not in the Placebo group
• Short-term Statin Therapy improved Endothelial function in SLE patients
Ferreira; Rheumatology; 2007* Indicates statistical significance
![Page 42: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/42.jpg)
Clinical Trials of Statins in Lupus
• 10 Trials registered with the NIH• 4 are recruiting• 4 are completed• 1 not recruiting; 1 is terminated• Trials using either Atorvastatin or Rosuvastatin• End-points: ↓Coronary Calcium; ↓Carotid
Disease; ↓ SLEDAI score, etc• To Date: no published results by my search
www.ClinicalTrials.gov
![Page 43: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/43.jpg)
Vascular Health and Disease
Moreno, P; JACC; 53 Nov 25, 2009
![Page 44: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/44.jpg)
Therapy: Post MI / Post ACS
• A—Aspirin and ACE Inhibitors (the “prils”)
• B—Beta Blockers and Blood Pressure
• C—Cholesterol / Cigarettes / Clopidogrel
• D—Diet (for Weight and Diabetes)
• E—Exercise and Education
Conti, CR Clin. Cardiology 2007
![Page 45: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/45.jpg)
Aspirin
• “Class I” for all CAD, MI and PVD patients
• 325 mg/day initially; 81-162mg/d long term
• Post MI: 35 vascular events prevented per 1000 patients x 30d
• 1 life saved at cost of $13 per year!
• ASA allergic?—can use Clopidogrel (Plavix)
![Page 46: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/46.jpg)
Angiotensin Converting Enzyme (ACE) Inhibitors (the “prils”)
• For post MI; overt CHF and Heart (LV) dysfunction even without symptoms
• HOPE trial: 25% women; had 22-25% decline in death rates in MI/CAD/Diabetic patients without CHF
• ex: Lisinopril 10-40 mg/d
• If ACE intolerant (allergy or dry cough) use and ARB (ex: Losartan)
![Page 47: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/47.jpg)
Lipid Lowering
• 13-33 death/Mi prevented per 1000 patients x 5 yr
• Measure lipids on initial blood draw
• Start Rx acutely—statins are Anti-Inflammatory (ex: Atorvastatin 10-80/d)
• Muscle: usually Myalgias—check CPK; rechallenge or use different statin (pravastatin)
• Liver: about 1/1000 asymptomatic mild elevation in liver enzymes
![Page 48: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/48.jpg)
NCEP-ATP III Guidelines
• Total Cholesterol
< 200 desirable
200-239 borderline high
> 240 high
![Page 49: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/49.jpg)
NCEP-ATP III Guidelines
• LDL
<100 optimal
100-129 near-opt.
130-159 borderline high
160-189 high
>190 very high
![Page 50: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/50.jpg)
Risk Factors (that modify LDL goal)
• Smoking• High BP• Low HDL (< 40)• Family history CAD• Central Obesity• Physical Inactivity• NOTE: Diabetes, PVD, Aortic Aneurysm and
Coronary Calcium are CHD “Equivalents”
![Page 51: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/51.jpg)
LDL Goals
Risk Factor LDL Goal 10 year event rate
CHD or Equivalent
< 100 mg/dl > 20%
2 or more Risk Factors
< 130 mg/dl 10-20%
0-1 Risk Factors
<160 mg/dl < 10%
![Page 52: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/52.jpg)
Framingham Risk: 10 vs 30 year(25 yo female)
Pencina, M; Circulation; 119; 2009
![Page 53: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/53.jpg)
Framingham Risk: 10 vs 30 year (45 yo female)
Pencina, M; Circulation; 119; 2009
![Page 54: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/54.jpg)
Therapy = “T.L.C.” (Therapeutic Lifestyle Change)
• Decrease Saturated Fat in diet
• Decrease Weight (ideal BMI = 18.5 to 24.9 kg/m2)
• Increase Physical Activity—even walking 30 min day
![Page 55: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/55.jpg)
Incorporating Triglycerides into the Mix
• The typical “Lupus” Lipid profile often has low HDL (“good” cholesterol), elevated Triglycerides and elevated levels of Lp(a) (a lipoprotein that ties into the clotting cascade)
• This profile is similar to the average patient with Diabetes
• Calculation of “Non-HDL” Cholesterol allows us to set goals with TG as well
• Lp(a) may be modifiable with exercise and Niacin
![Page 56: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/56.jpg)
Incorporating Triglycerides(Total Chol – HDL = “Non HDL” )
Risk LDL Goal Non-HDL Goal
CHD or equiv. <100 <130
2 or more risk factors
<130 <160
0-1 risk factors <160 <190
![Page 57: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/57.jpg)
Lipid Lowering, cont’d
• High Total and LDL Cholest Statins
(zocor, lipitor,etc)
• High Trig and Low HDL Cholest Fibrates (lopid, tricor)
• High LDL and Trig and low HDL Cholest Niacin (niaspan)
• High Triglycerides prescript. Fish oil (Omega 3 FAs) (lovaza)
![Page 58: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/58.jpg)
Diet Modification: Healthy Choices
• Fruits and Vegetables• Whole Grain and High Fiber• Oily (cold water) fish 2 x / week• Alcoholic drink not > 1/day• Sodium (Na+) < 2.3 gram/day• Saturated Fat < 10% of total calories• Limit Trans-Fat: Baked Goods and Fried
Foods
![Page 59: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/59.jpg)
Hormone Therapy
• Estrogen Replacement with or w/o Progestin—of no benefit in preventing CHD
• Small but increased risk of Stoke
• Use short term for peri-menopausal Sx only
• Estrogen receptor modulators (raloxifene) of no benefit for CHD.
![Page 60: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/60.jpg)
Cardiac (Exercise) Rehab
• Prevents 23 deaths per 1000 patients
• Safety: Mortality 1 / 784,000 pt-hours
• Cost: $1200 / QOL-year (comparable to Left main surgery!) By comparison, Dialysis costs $40,000 / QOL-yr
• Usually 3 x /week for 12-16 weeks
• YET-- < 20% of patients get referred??
![Page 61: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/61.jpg)
Smoking Cessation
• Smokers have 3 x the risk of MI of non-smokers
• Cessation prevents 70 deaths per 1000 patients x 1 year
• YET: few are asked and few are counseled
• My motto: “Attack ‘em in the hospital and kick ‘em when they’re down”!!
![Page 62: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/62.jpg)
Still Lacking Evidence
• Although it’s argued that Lupus and other disorders (RA) are “vascular risk equivalents” this is NOT proven or accepted
• No evidence (yet) for routine (imaging) screening in Lupus for asymptomatic vascular disease
• No evidence (yet) for empiric therapy with statins, etc in Lupus
• Major organizations (ACC, AHA, ACR) as yet, have no specific guidelines for Lupus and Vascular disease (“evidence-based medicine”)
![Page 63: Lupus and cardiovascular disease](https://reader033.vdocument.in/reader033/viewer/2022060108/55505fa0b4c905c0448b50c1/html5/thumbnails/63.jpg)
Do…..
• See your MD regularly and report new signs or symptoms
• If you have routine vascular risk factors (or a prior “event”, take your medications (statins, aspirin, etc)
• Take the lowest dose of steroids and continue antimalarials
• Exercise 4-5 x week for 30-40 min (even a good walk)
• Stop Smoking!• Eat fresh and “colorful”
foods—avoid processed• If asked to participate in
clinical trials—consider it strongly--that’s how we develop evidence-based treatment